ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Animal models"

  • Abstract Number: 1725 • 2014 ACR/ARHP Annual Meeting

    The SYK Inhibitor Fostamatinib Limits Tissue Damage and Fibrosis in a Bleomycin-Induced Scleroderma MOUSE MODEL

    Omer Nuri Pamuk1, Guray Can2, Suleyman Ayvaz3, Turan Karaca4, Gulsum Pamuk5, Selim Demirtas6 and George C. Tsokos7, 1Rheumatology, Trakya University Medical Faculty, Edirne, Turkey, 2Gastroenterology, Trakya University Medical Faculty, Edirne, Turkey, 3Pediatric Surgery, Trakya University Medical Faculty, Edirne, Turkey, 4Histology, Trakya University Medical Faculty, Edirne, Turkey, 5Hematology, Trakya University Medical Faculty, Edirne, Turkey, 6Trakya University Medical Faculty, Edirne, Turkey, 7Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA

    Background/Purpose The possible antifibrotic effects of various kinase inhibitors has been studied before in SSc. Spleen tyrosine kinase (Syk) is a protein tyrosine kinase which…
  • Abstract Number: 766 • 2014 ACR/ARHP Annual Meeting

    Endothelial Fli1 Deficiency Delays Wound Healing Due to Impaired Anastomosis of Newly Formed Vessels – a Possible Mechanism of Refractory Skin Ulcers in Systemic Sclerosis

    Yoshihide Asano1 and Maria Trojanowska2, 1Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, 2Arthritis Center, Boston University, Boston, MA

    Background/Purpose Systemic sclerosis (SSc) is a multisystem inflammatory and vascular disease resulting in fibrosis of the skin and certain internal organs. Although the pathogenesis of…
  • Abstract Number: 337 • 2014 ACR/ARHP Annual Meeting

    Effect of Etanercept on Endothelial Dysfunction in Rat Adjuvant-Induced Arthritis

    Perle Totoson1, Katy Maguin-Gaté1, Daniel Wendling2 and Céline Demougeot1, 1EA 4267 « Fonctions et Dysfonctions Epithéliales » , Faculté de Médecine-Pharmacie, Besançon, France, 2Service de Rhumatologie, CHU J Minjoz, Besancon, France

    Background/Purpose Growing evidence indicate that Rheumatoid Arthritis (RA)-associated increase in cardiovascular risk is secondary to the presence of endothelial dysfunction (ED). Although Tumor Necrosis Factor…
  • Abstract Number: 2905 • 2014 ACR/ARHP Annual Meeting

    The IL-6/Th17 Axis Promotes Autoantibody-Associated Autoimmune Valvular Carditis in Mice

    Jennifer L. Auger1, Brianna J. Engelson2, Yaya Wang3, Erik J. Peterson4 and Bryce A. Binstadt5, 1Center for Immunology and Department of Pediatrics, University of Minnesota, Minneapolis, MN, 2Pediatrics, University of Minnesota, Minneapolis, MN, 3Medicine, University of Minnesota, Minneapolis, MN, 4University of Minnesota, Minneapolis, MN, 5Pediatric Rheumatology, University of Minnesota, Minneapolis, MN

    Background/Purpose: Autoimmune valvular carditis occurs in patients with systemic lupus erythematosus, rheumatoid arthritis and rheumatic fever, but the pathogenic mechanisms remain incompletely defined. Spontaneous autoimmune…
  • Abstract Number: 1706 • 2014 ACR/ARHP Annual Meeting

    Prevention of SU5416-Induced Pulmonary Hypertension in a TGFβ Dependent Genetic Mouse Model of Scleroderma Using the Endothelin Receptor Antagonist Macitentan

    Emma C. Derrett-Smith1, Vincent Sobanski2, Sarah Trinder3, Adrian J Gilbane3, Marc Iglarz4, David J. Abraham3, Alan M. Holmes5 and Christopher P Denton6, 1Centre for Rheumatology and Connective Tissue Diseases,, UCL Medical School Royal Free Campus, London, United Kingdom, 2UCL Medical School, London, United Kingdom, 3Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, 4Actelion Pharmaceuticals Ltd., Allschwil, Switzerland, 5Centre for Rheumatology and Connective Tissue Diseases, UCL, London, United Kingdom, 6Centre for Rheumatology and Connective Tissue Disease, UCL Medical School Royal Free Campus, London, United Kingdom

    Background/Purpose: Pulmonary arterial hypertension (PAH) is an important complication of systemic sclerosis (SSc) that occurs in around 10% of cases.  We have previously shown that…
  • Abstract Number: 744 • 2014 ACR/ARHP Annual Meeting

    Integrin Inhibitor Modulates Pulmonary Fibrosis in the Reactive Oxygen Species Murine Model of Systemic Sclerosis

    Gianluca Bagnato1, Alessandra Bitto2, Natasha Irrera2, Gabriele Pizzino2, Neal Roberts3, Domenica Altavilla2, Francesco Squadrito2, Antonino Saitta4 and Gianfilippo Bagnato5, 1Rheumatology, University of Messina, Messina, Italy, 2Pharmacology, University of Messina, Messina, Italy, 3University of Louisville, Louisville, KY, 4Internal Medicine, University of Messina, Messina, Italy, 5Via C. Colombo, 41, Universita Messina, Villafranca Tirrena, Italy

    Background/Purpose: Systemic sclerosis (SSc) is an acquired connective tissue disorder in which inflammation, immune dysregulation and vascular damage lead to fibroblast activation that results in…
  • Abstract Number: 336 • 2014 ACR/ARHP Annual Meeting

    The Additive Inflammatory in Vivo and in Vitro Effects of Thymic Stromal Lymphopoietin (TSLP) and IL-7 in Arthritis Underscore the Therapeutic Rationale for blockade of Their Common Receptor Subunit

    M.R. Hillen1,2, S.A.Y. Hartgring1,2, T.R.D.J. Radstake2,3, C.E. Hack1,2, F.P.J.G. Lafeber1 and J.a.G. van Roon1,2, 1Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands, 2Laboratory for Translational Immunology, UMC Utrecht, Utrecht, Netherlands, 3Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose Interleukin (IL)-7 and thymic stromal lymphopoietin (TSLP) are cytokines that signal through the IL-7Ra subunit and play proinflammatory roles in experimental arthritis and rheumatoid…
  • Abstract Number: 2878 • 2014 ACR/ARHP Annual Meeting

    G Protein Signaling Modulator 3 (GPSM3) Deficiency Is Protective in Inflammatory Arthritis Models and Altered GPSM3 Gene Products Correlate with Single Nucleotide Polymorphisms in Humans

    Teresa K. Tarrant1, D. Stephen Serafin2, Elizabeth Sugg2, Roman Timoshchenko2, Matthew J. Billard2, David P. Siderovski3 and Kristy Richards4, 1Medicine/Rheumatology, Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 2Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 3Physiology and Pharmacology, West Virginia University School of Medicine, Morgantown, WV, 4Medicine, Dept. of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC

    Background/Purpose GPSM3, a newly described regulator of heterotrimeric G protein signaling, is selectively expressed in hematopoietic cells with high expression in monocytes.  We have shown…
  • Abstract Number: 1718 • 2014 ACR/ARHP Annual Meeting

    B Cell Subsets Homeostasis and Functional Properties Are Altered in a Murine Model of Systemic Sclerosis

    Sébastien Sanges1,2,3, Niloufar Kavian4, Carine Hauspie1,3,5, Carole Nicco4, Thomas Guerrier1,3, Virginie Dutoit-Lefèvre1,3, Guillaume Lefèvre1,2,5,6, Alexandra Forestier1,2,3, Vincent Sobanski1,2,6, Christelle Faveeuw7, Myriam Labalette1,3,5, Frédéric Batteux4, David Launay1,2,3 and Sylvain Dubucquoi1,3,5, 1Université Lille Nord de France, Faculté de Médecine Henri Warembourg, Lille, Lille, France, 2Service de médecine interne, Centre National de Référence de la Sclérodermie Systémique, Hôpital Claude Huriez, CHRU Lille, Lille, France, 3EA 2686, Lille, Lille, France, 4Université Paris Descartes, EA 1833, Hôpital Cochin, AP-HP, Paris, Paris, France, 5Institut d’Immunologie, Centre de Biologie-Pathologie-Génétique, CHRU Lille, Lille, France, 6EA 2686, Lille, LILLE, France, 7Institut National de la Santé et de la Recherche Médicale Unité 547, Institut Pasteur de Lille, Institut Fédératif de Recherche 142, Université de Lille Nord de France, Lille, France

    Background/Purpose Systemic sclerosis (SSc) is a multi-organ fibrotic disease associated with auto-immune abnormalities. Several clinical and experimental observations suggest that B cells are involved in…
  • Abstract Number: 756 • 2014 ACR/ARHP Annual Meeting

    Nucleosome, a Basic Repeating Unit of Chromatin, in Patients with Systemic Sclerosis: Possible Association with Immunological Abnormalities Via Abnormal Activation of T and B Cells

    Ayumi Yoshizaki1, Yoshihide Asano2, Takashi Taniguchi1, Ryosuke Saigusa1, Kouki Nakamura1, Takashi Yamashita1, Takehiro Takahashi1, Tetsuo Toyama1, Yohei Ichimura1, Zenshiro Tamaki1, Miki Miyazaki1 and Shinichi Sato1, 1Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, 2University of Tokyo Graduate School of Medicine, Tokyo, Japan

    Background/Purpose Nucleosome is the basic repeating units of chromatin. Each nucleosome is composed of an inner core of histones H3 and H4 and an outer…
  • Abstract Number: 20 • 2014 ACR/ARHP Annual Meeting

    High Systemic LDL Cholesterol Levels during Experimental Osteoarthritis Lead to Increased Synovial Activation and Ectopic Bone Formation at End-Stage Osteoarthritis, While Excessive Levels Accelerate Development of Joint Pathology Already at Early-Stage Osteoarthritis

    Wouter de Munter, Martijn H. van den Bosch, Annet W. Sloetjes, Peter M. van der Kraan, Wim B. van den Berg and Peter L. van Lent, Experimental Rheumatology (272), Radboud university medical center, Nijmegen, Netherlands

    Background/Purpose: A relation between osteoarthritis (OA) and the metabolic syndrome has long been established. One of the characteristics of the metabolic syndrome is increased cholesterol…
  • Abstract Number: 2863 • 2014 ACR/ARHP Annual Meeting

    IgG Antiphospholipid Antibodies Enhance Stroke Damage: An in Vivo Ischemia/Reperfusion Study

    Charis Pericleous1, Valerie Taylor2, Lauren Bourke3, Daniel Stuckey2, Jed Wingrove4, Mark Lythgoe5, Silvia S. Pierangeli6, Anisur Rahman3, Ian Giles1 and Yiannis Ioannou7, 1Centre for Rheumatology, Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, 2Centre for Advanced Biomedical Imaging (CABI), University College London, London, United Kingdom, 3Centre for Rheumatology Research, University College London, London, United Kingdom, 4Centre for Advanced Biomedical Imaging, University College London, London, United Kingdom, 5Centre for Advanced Biomedical Imaging, Centre for Advanced Biomedical Imaging (CABI), University College London, London, United Kingdom, 6Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, 7Centre for Rheumatology Research, University College Hospital London, London, United Kingdom

    Background/Purpose Circulating pathogenic antiphospholipid antibodies (aPL) are the hallmark of antiphospholipid syndrome (APS) and a major risk factor for ischemic stroke, with up to one…
  • Abstract Number: 1495 • 2014 ACR/ARHP Annual Meeting

    Preclinical and Clinical Phase I Profile of MK-8457, a Selective Spleen Tyrosine Kinase and Zeta-Chain-Associated Protein Kinase 70 Inhibitor, Developed for the Treatment of Rheumatoid Arthritis

    Gene Marcantonio1, Alan Bass2, Gretchen Baltus3, Judith Boice1, Hongmin Chen4, Michael Crackower5, Jeroen Elassaiss-Schaap6, Michael Ellis7, Tomoko Freshwater8, Francois Gervais9, Jane Guo10, Sammy Kim9, Lily Moy5, Alan Northrup7, Jie Zhang-Hoover4, Mathew Maddess11, Richard Miller12, Marcella Ruddy5, Stella Vincent13, Haoling Weng1 and Hani Houshyar14, 1Merck & Co., Whitehouse Station, NJ, 2Safety Assessment, Merck & Co., Boston, MA, 3Immunomodulatory Regulators, Merck & Co., Boston, MA, 4Pharmacology, Merck & Co., Boston, MA, 5Merck & Co., Boston, MA, 6Clinical PK-PD, Merck & Co., Oss, Netherlands, 7Medicinal Chemistry, Merck & Co., Boston, MA, 8PPDM Early Stage, Merck & Co., Rahway, NJ, 9Cell Pathways and Proteins, Merck & Co., Boston, MA, 10Immunology, Merck & Co., Boston, MA, 11Discovery Process Chemistry, Merck & Co., Boston, MA, 12Biochemistry & Biophysics, Merck & Co., Boston, MA, 13PPDM Preclinical ADME, Merck & Co., Boston, MA, 1433 Avenue Louis Pasteur, Merck & Co., Boston, MA

    Background/Purpose: Spleen tyrosine kinase (SYK) is a potential target for treatment of several diseases including rheumatoid arthritis.  SYK is a member of the Zeta-chain-associated protein…
  • Abstract Number: 660 • 2014 ACR/ARHP Annual Meeting

    Microthrombotic Renal Vascular Lesions Are Associated to Increased Renal Inflammatory Infiltration in a Mouse Model of Lupus Nephritis

    María Galindo1, Elena Gonzalo-Gil2, Oscar Toldos3, Carmen García-Herrero2, Alicia Usategui1, Sonia Pérez-Yagüe4, Gabriel Criado5, Domingo F. Barber4 and Jose L. Pablos1, 1Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, 2Department of Rheumatology, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, 3Servicio de Anatomia Patologica, Hospital 12 de Octubre, Madrid, Spain, 4Centro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain, 5Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain

    Background/Purpose In patients with lupus nephritis (LN), acute renal vascular and atherosclerotic lesions correlate with the degree of inflammation regardless the presence of antiphospholipid antibodies.…
  • Abstract Number: 2796 • 2014 ACR/ARHP Annual Meeting

    A Novel Mouse Model of Osteochondromagenesis By Deleting NFATc1 in Mesenchymal Progenitors and Postnatal Chondrocytes

    Xian-Peng Ge1, Susan Y. Ritter2, Julia F. Charles3, Kelly Tsang2 and Antonios O. Aliprantis2, 1Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 3Rheumatology, Allergy and Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Osteochondromas are the most common benign bone tumor and are characterized by cartilage-capped bony projections from the external surface of bone. These lesions may…
  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 25
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology